
Jan 12 (Reuters) - Moleculin Biotech Inc MBRX.O:
MOLECULIN ACCELERATES OUTLOOK INTO 2026 WITH FIRST PIVOTAL TRIAL UNBLINDING ON TRACK, GLOBAL TRIAL EXPANSION, AND MULTIPLE EXTERNALLY/IIT FUNDED CLINICAL PROGRAMS
MOLECULIN BIOTECH INC - FIRST MIRACLE TRIAL UNBLINDING EXPECTED Q1 2026; GLOBAL TRIAL NOW SPANS NINE COUNTRIES
MOLECULIN BIOTECH INC - PRIMARY EFFICACY DATA FOR MIRACLE EXPECTED IN 2028